Tovorafenib
- Generic Name
- Tovorafenib
- Drug Type
- Small Molecule
- Chemical Formula
- C17H12Cl2F3N7O2S
- CAS Number
- 1096708-71-2
- Unique Ingredient Identifier
- ZN90E4027M
- Background
Tovorafenib (TAK-580) is under investigation in clinical trial NCT02723006 (Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma).
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Phase 1
Completed
- Conditions
- Advanced Nonhematologic Malignancies
- Interventions
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02327169
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT01425008
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath